Lipocine Inc. (OTCQB/OTCBB:LPCN), a specialty
pharmaceutical company, announced today that it has changed its trading
symbol from OTCBB:MBARD to OTCQB/OTCBB:LPCN. On July 24, 2013, Lipocine
successfully completed a reverse merger with Marathon Bar Corp. The
combined company is focused solely on the business of Lipocine.
About Lipocine Inc.
Lipocine Inc. is a specialty pharmaceutical company developing
innovative products for use in men’s and women’s health using its
proprietary drug delivery technologies. Lipocine’s lead product
candidate, LPCN 1021, is Phase III ready and is targeted to treat
symptoms of low testosterone for men in need of testosterone replacement
therapy. This product candidate is designed to provide twice-a-day oral
dosing. Additional pipeline candidates include LPCN 1111, a
next-generation longer-acting oral testosterone therapy product, and
LPCN 1107, potentially the first oral product for the prevention of
pre-term birth.
Forward-Looking Statements
Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995 and include all statements relating to the proposed use of
proceeds and the potential benefits of Lipocine’s product candidates.
Investors are cautioned that all forward-looking statements involve risk
and uncertainties, including without limitation the risks related to the
receipt of regulatory approvals and other risks detailed in Lipocine's
filings with the U.S. Securities and Exchange Commission, including
without limitation its Current Report on Form 8-K, dated July 24, 2013.
Copyright Business Wire 2013